N-{4-[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl]-3-methylphenyl}-2-methylbenzamide

• ChemBase ID: 178726
• Molecular Formular: C26H25ClN2O3
• Molecular Mass: 448.9413
• Monoisotopic Mass: 448.15537035
• SMILES: c1(ccccc1C)C(=O)Nc1ccc(c(c1)C)C(=O)N1CCC[C@H](c2c1ccc(c2)Cl)O
• Canonical SMILES: Clc1ccc2c(c1)[C@H](O)CCCN2C(=O)c1ccc(cc1C)NC(=O)c1ccccc1C
• InChI: InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)/t24-/m1/s1
• InChIKey: GYHCTFXIZSNGJT-XMMPIXPASA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: N-{4-[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl]-3-methylphenyl}-2-methylbenzamide
• IUPAC Traditional name: tolvaptan; N-{4-[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl]-3-methylphenyl}-2-methylbenzamide
• Synonyms: N-[4-[[(5R)-7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl]carbonyl]-3-methylphenyl]-2-methylbenzamide; (R)-(+)-OPC 41061; (R)-(+)-Tolvaptan; Samsca; OPC-41061; Tolvaptan

Database IDs

• CAS Number: 150683-30-0; 331947-66-1
• PubChem SID: 164234636
• PubChem CID: 443894

CALCULATED PROPERTIES

• Acid pKa: 11.755283
• H Acceptors: 3
• H Donor: 2
• LogD (pH = 5.5): 5.3501835
• LogD (pH = 7.4): 5.3501654
• Log P: 5.3501835
• Molar Refractivity: 129.1552 cm^3
• Polarizability: 48.183975 Å^3
• Polar Surface Area: 69.64 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: false

PROPERTIES

Pharmacology Properties

• Mechanism of Action: Vasopressin V2 receptor antagonist

Product Information

• Application(s): Used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).

DETAILS

Toronto Research Chemicals - T536640

An enantiomer of Tolvaptan. It is a selective, competitive arginine vasopressin V2 receptor antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic

REFERENCES

• Paterna, S., et al.: Eur. J. Heart Fail, 2, 305 (2000)
• Udelson, J., et al.: Circulation, 104, 2417 (2000)
• Goldsmith, S., et al.: J. Am. Coll Cardiol., 46, 1785 (2000)
• Schrier, R., et al.: N. Engl. J. Med., 355, 2099 (2000)
• 2. Shoaf S, Elizari M, Wang Z et al. (2005). "Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias". J Cardiovasc Pharmacol Ther 10 (3):
• 165?1.
• 3. Gheorghiade M, Gattis W, O'Connor C et al. (2004). "Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial". JAMA 291 (
• 16): 1963?1.
• 1. Gheorghiade M, Niazi I, Ouyang J et al. (2003). "Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial". Circulation
• 107 (21): 2690?